Clinical trial
A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of…
NCT00427362 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00427362 |
|---|---|
| Title | A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM) |
| Official title | A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM) |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriatic Arthritis |
| Intervention type | Drug |
| Interventions | Adalimumab |
| Enrollment | 127 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2007 |
| First posted | Jan 29, 2007 |
| Last update posted | May 2, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: